Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01674010 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder
A Phase 2 study, sponsored by OPKO Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 309
- Enrollment target
NCT01674010 is a Phase 2 study that was terminated before completion, run by OPKO Health. The registered enrollment target is 309 participants.
The verdict
NCT01674010, a Phase 2 study, was terminated before completion, sponsored by OPKO Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 309 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine whether ELND005 is effective in the maintenance treatment of bipolar 1 disorder when added to other therapies.
Interventions
- DRUG Placebo
- DRUG Lamotrigine
- DRUG ELND005
- DRUG Valproic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 309 participants |
| Start Date | 2012-08 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01674010
The ClinicalTrials.gov registry entry for NCT01674010 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 309 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OPKO Health, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01674010 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01674010 about?
NCT01674010 is a clinical study titled "Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder". The primary purpose of this study is to determine whether ELND005 is effective in the maintenance treatment of bipolar 1 disorder when added to other therapies.
What is the current status of trial NCT01674010?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 309 participants. The study started on 2012-08. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01674010?
The interventions under investigation include: Placebo (DRUG), Lamotrigine (DRUG), ELND005 (DRUG), Valproic acid (DRUG).
Who is sponsoring clinical trial NCT01674010?
This trial is sponsored by OPKO Health, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.